{"preliminary_commentary":{"by_channel":{"x_thread":9,"youtube":2,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05795101\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"TRUDI","nct_id":"NCT05795101","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=trudi-nct05795101. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TRUDI","arms":[{"description":"Participants will be enrolled into one of two cohorts: HER2 positive IBC (cohort 1) and HER2 low IBC (cohort 2).\n\n* HER2-positive determined locally by the current ASCO/CAP guidelines\n* Participants will receive trastuzumab deruxtecan plus durvalumab for eight cycles prior to surgery. (Cycle Length is 21 days)\n* After surgery, Participants will receive therapy per physician's choice and to reflect current standard of care.","label":"HER2 Positive","type":"EXPERIMENTAL"},{"description":"Participants will be enrolled into one of two cohorts: HER2 positive IBC (cohort 1) and HER2 low IBC (cohort 2)\n\n* HER2-low tumor expression (IHC 2+/ISH-, IHC 1+/ISH-, or IHC 1+/ISH untested)\n* Participants will receive trastuzumab deruxtecan plus durvalumab for eight cycles prior to surgery (Cycle Length is 21 days)\n* After surgery, Participants will receive therapy per physician's choice and to reflect current standard of care.","label":"HER2-Low","type":"EXPERIMENTAL"}],"collaborators":["AstraZeneca","Daiichi Sankyo"],"completion_date":{"date":"2032-12-01","type":"ESTIMATED"},"conditions":["Invasive Breast Cancer","Inflammatory Breast Cancer Stage III","HER2-positive Breast Cancer","HER2 Low Breast Adenocarcinoma","Breast Cancer"],"enrollment":{"count":63,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Trastuzumab deruxtecan","otherNames":["Enhertu"],"type":"DRUG"},{"name":"Durvalumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-09","lead_sponsor":"Filipa Lynce, MD","official_title":"TRUDI: A Phase II Study of Neoadjuvant Trastuzumab Deruxtecan and Durvalumab for Stage III, HER2-expressing Inflammatory Breast Cancer","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-12-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Pathological complete response (pCR) Rate","timeFrame":"Assessed on surgical tissue: surgery occurs no later than 6 weeks post 8 cycles of neo-adjuvant therapy (one cycle=21 days)"}],"references":[],"start_date":{"date":"2023-05-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"TRUDI: TDXD+Durva in HER2+/Low IBC","url":"https://clinicaltrials.gov/study/NCT05795101"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/trudi-nct05795101"}